TLDR Brent crude rose to $72.54 a barrel and West Texas Intermediate climbed to $66.89 after US-Iran nuclear talks in Geneva ended without a deal Iran’s foreignTLDR Brent crude rose to $72.54 a barrel and West Texas Intermediate climbed to $66.89 after US-Iran nuclear talks in Geneva ended without a deal Iran’s foreign

Oil Prices and Energy Stocks (XOM, CVX, COP) Rise After US-Iran Nuclear Talks Stall

2026/02/27 21:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Brent crude rose to $72.54 a barrel and West Texas Intermediate climbed to $66.89 after US-Iran nuclear talks in Geneva ended without a deal
  • Iran’s foreign minister called the talks one of the “most serious and longest rounds of negotiations” and said both sides made “good progress”
  • The next round of talks is expected within a week, likely in Vienna
  • Oil stocks Exxon, Chevron, and ConocoPhillips all rose in premarket trading
  • An OPEC+ supply meeting is scheduled for Sunday, with concerns about a potential oil glut weighing on the market

Oil prices jumped on Friday after the latest round of nuclear talks between the United States and Iran ended without a deal. The two countries held discussions in Geneva on Thursday, and while no agreement was reached, both sides said talks would continue.

Brent crude futures rose to $72.54 a barrel, up 2.4% on the day. West Texas Intermediate climbed 2.6% to $66.89 a barrel.

Brent Crude Oil Last Day Financ (BZ=F)Brent Crude Oil Last Day Financ (BZ=F)

Iran’s Foreign Minister Abbas Araghchi described the Geneva session as one of the “most serious and longest rounds of negotiations” held between the two sides. He said “good progress” was made during the talks.

Oil prices have swung sharply in the past 24 hours. Traders are balancing the possibility of a diplomatic deal against the risk of US military action, either of which would affect global oil supply.

Energy Stocks Move Higher

Energy stocks gained on the back of rising oil prices. Exxon rose 1.1% in premarket trading and Chevron was up 0.8%. ConocoPhillips added 0.6%.

The moves reflect investor sensitivity to any developments in the Middle East that could disrupt oil production or shipping routes.

Matt Britzman, senior equity analyst at Hargreaves Lansdown, noted that mixed signals from both sides kept traders cautious despite the hint of progress. He said attention is now turning to Sunday’s OPEC+ supply meeting.

OPEC+ Meeting in Focus

Concerns about an emerging oil glut are hanging over the market ahead of the OPEC+ gathering. The group is expected to discuss output levels, and any decision to increase supply could weigh on prices.

That tension between geopolitical risk and potential oversupply is keeping oil markets volatile. Prices remain sensitive to any new developments from either the Iran talks or the OPEC+ meeting.

As of Friday morning, Brent crude was trading at $71.36 a barrel and West Texas Intermediate was at $65.82, reflecting a slight pullback from earlier highs but still well above Thursday’s close.

The post Oil Prices and Energy Stocks (XOM, CVX, COP) Rise After US-Iran Nuclear Talks Stall appeared first on CoinCentral.

Market Opportunity
Convex Finance Logo
Convex Finance Price(CVX)
$2.097
$2.097$2.097
+6.55%
USD
Convex Finance (CVX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09